Quantcast

Global Progressive Supranuclear Palsy Therapeutics Market Analysis Report 2019-2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Progressive Supranuclear Palsy Therapeutics Market 2019-2023”

report has been added to ResearchAndMarkets.com’s
offering.

The progressive supranuclear palsy therapeutics market will register a
CAGR of nearly 5% by 2023.

The increasing strategic alliances are expected to trigger the
progressive supranuclear palsy therapeutics market growth during the
forecast period.

Vendors in the market are entering into strategic alliances for
co-developing and co-commercializing drugs of for licensing the drugs to
large pharmaceutical vendors including the academic institutions and
several small pharmaceutical vendors lacking the advanced manufacturing
processes.

Increasing strategic alliances

The increasing strategic alliances are likely to result in the faster
completion of the study leading to the quicker approval of the
therapies, thus resulting in the growth of the global progressive
supranuclear palsy therapeutics market during the forecast period.

Adverse side effects

The presence of strong adverse side effects of these drugs is currently
a major challenge acting as a barrier to the market growth and is
expected to remain a challenge to the growth of the global progressive
supranuclear palsy therapeutics market during the forecast period.

Competitive Landscape

The market appears to be highly concentrated. This market research
report will help clients identify new growth opportunities and design
unique growth strategies by providing a comprehensive analysis of the
market’s competitive landscape and offering information on the products
offered by companies.

Key Players

  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Merck & Co. Inc.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Dopamine – Market size and forecast 2018-2023
  • Anticholinergic agents – Market size and forecast 2018-2023
  • Tricyclic antidepressants – Market size and forecast 2018-2023
  • Others – Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America – Market size and forecast 2018-2023
  • Europe – Market size and forecast 2018-2023
  • Asia – Market size and forecast 2018-2023
  • RoW – Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Merck & Co. Inc.

For more information about this report visit https://www.researchandmarkets.com/r/yrda0z

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.